

Original Research Article

Prevalence and laboratory profile of hepatitis B virus co-infected Nigerian children with human immunodeficiency virus infection.

ABSTRACT

Aims: To determine the prevalence of HBV co-infection in HIV-infected children and compare the baseline laboratory profile of mono-infected and co-infected patients.

Study Design: This was a retrospective cohort study.

Place and Duration of Study: AIDS Prevention Initiative in Nigeria (APIN)-supported HIV clinic of Jos University Teaching Hospital, Jos, Nigeria between January 2008 and December 2012.

Methodology: We reviewed the clinical records of 452 treatment-naïve children aged 2 months to 15 years confirmed to be HIV positive with Polymerase Chain Reaction (PCR) or Western blot enrolled at the clinic within the stated period. Their baseline HBsAg test results, CD4⁺T cell count for children ≥5years or CD4⁺T cell % generated by automated method for children <5years, viral load and alanine transaminase (ALT) levels were analysed.

Results: Three hundred and ninety-four (87.2%) were mono-infected with HIV while 58 (12.8%) were co-infected with HIV and HBV. The median viral load was 4.6 log copies/mL for mono-infected compared to 4.7 log copies/mL for HIV/HBV ($P = .48$). The median CD4⁺T cell count was 366 cells/μL for mono-infected compared to 332 cells/μL for HIV/HBV ($P = .64$). The median CD4⁺T cell % was 19% for mono-infected compared to 17% for HIV/HBV ($P = .29$). The median ALT level for the whole was 23 IU/L for mono-infected compared to 26 IU/L for HIV/HBV ($P = .15$). However the median ALT level for mono-infected children aged 11-15 years was 28 IU/L compared to 43 IU/L for co-infected children of same age ($P = .008$).

Conclusion: A high rate of hepatitis B co-infection was observed in HIV-infected children at our centre; however more severe HIV disease was not observed. Older children co-infected with HBV had significantly higher ALT levels compared to their mono-infected counterparts. Early detection is therefore necessary in order to develop an appropriate treatment plan for children co-infected with HIV and HBV.

Keywords: HIV, hepatitis B, co-infection, CD4⁺T, viral load, alanine transaminase, Nigeria.

1. INTRODUCTION

Human immunodeficiency virus (HIV) and hepatitis B virus (HBV) are the two most common chronic viral infections seen in the world. [1, 2] With an estimated 260,000 children infected with HIV at the end of 2011, Nigeria accounts for more than 10% of the global paediatric HIV burden. [3] Nigeria is also known to be highly endemic for HBV infection. [4] Co-infection with HBV is common among HIV infected children in sub-Saharan African countries. [5-8] The two viruses share common modes of transmission and hence co-exist in the same host at significantly high rates. HBV infections acquired in the perinatal period and early childhood are more likely to lead to chronic infection. [9-10] HIV positive individuals, particularly those with suppressed immune systems, are less likely to respond to vaccination against HBV and are more likely to develop chronic disease after being exposed to HBV. [10] As more HIV-infected children are commenced on highly active anti-retroviral therapy (HAART), they will live longer and co-infection with the hepatitis viruses may become a major health care catastrophe in the coming years especially in resource-limited countries.

The effect of HIV infection on progression of HBV infection in adults is well established. [11-12] Co-infection with HIV modifies the natural history of HBV infection, increasing the rate of viral replication, risk of carriage and chronic hepatitis. [11] HBV infection also increases the toxicity to antiretroviral medications. [12] Co-infection with HBV may lead to rapid progression of HIV

disease. [7] Previous studies in adults in Nigeria showed that HIV-infected patients with HBV co-infection had higher HIV ribonucleic acid (RNA) loads and more severe immune suppression prior to initiation of HAART compared to HIV mono-infected patients. [13-15]

There is limited information on the effect HBV co-infection has on baseline laboratory profile of HIV-infected children in sub-Saharan African countries. This study therefore aimed to determine the prevalence and laboratory profile of HIV/HBV co-infected children in Jos, Nigeria.

2. MATERIAL AND METHODS

2.1 Background of study area

The study was carried out at AIDS Prevention Initiative in Nigeria (APIN)-supported HIV clinic of Jos University Teaching Hospital, Jos, Plateau State, Nigeria. The programme cares for patients in and outside Plateau state. HIV care, treatment and support services are free for all patients enrolled in the program.

2.2 Study Design

This was a retrospective cohort study.

2.3 Ethical Consideration

A written informed consent was obtained from parents/guardians for use of data for research. Ethical clearance was obtained from the Ethical committee of Jos University Teaching Hospital and the Institution Review Board of Harvard School of Public Health.

2.4 Data Collection

The medical records of all treatment-naïve HIV-positive children enrolled in the Paediatric ART program between January 2008 and December 2012 were reviewed for the study. HIV was confirmed by either deoxyribonucleic acid Polymerase Chain Reaction (DNA PCR) for children

<18 months or Western blot for children ≥18 months. The baseline laboratory parameters assessed include HBV, CD4⁺T cell count and CD4⁺T cell percent, viral load, and alanine transaminase (ALT). HBV surface antigen (HBsAg) was used to categorize hepatitis status of the patients. HBsAg was determined using enzyme immunoassay (EIA) (Monolisa HBsAg Ultra3; Bio-Rad). HIV RNA levels were measured using Roche COBAS Amplicor HIV-1 monitor test version 1.5 (Roche Diagnostics, GmbH, Mannheim, Germany) with a detection limit of 400 copies/ml. Flow cytometry was used to determine CD4⁺T cell count (Partec, GmbH Munster, Germany) and the CD4⁺T percent determined by automated method.

2.5 Statistical Analysis

The baseline laboratory parameters of HIV mono-infected patients were compared with those that were co-infected with HBV using nonparametric univariate methods; the Kruskal-Wallis test was used for continuous variables. Linear regression analyses were used to determine whether HBV status was associated with baseline CD4⁺T cell counts/percent, viral load, or ALT values. *P* value <0.05 was considered significant. Analysis was done with EpiInfo version 3.5.4.

3. RESULT

Four hundred and fifty-two treatment-naïve children aged 2 months to 15 years were enrolled between January 2008 and December 2012. Males were 254 (56.2%) while females were 198 (43.8%). The mean age for the males was 4.24±2.78 years and that of the females was 5.34±3.55 years (*P* = .06). Three hundred and ninety-four (87.2%) were mono-infected with HIV while 58 (12.8%) were co-infected with HIV and HBV. The characteristics of the patients are shown in Table 1.

Table 1: Characteristics of the patients

Characteristic	Total (%)
----------------	-----------

Sex	
Males	254 (56.2)
Females	198 (43.8)
Age	
<1year	94 (20.8)
1-5years	227 (50.2)
6-10years	111 (24.6)
11-15years	20 (4.4)
Hepatitis B status	
Negative	394 (87.2)
Positive	58 (12.8)

91

92 Based on age group, 9.6% of those aged <1 year were co-infected with HBV compared to
93 11.9% of those aged 1-5 years, 13.5% of those aged 6-10 years and 35% of those aged 11-15
94 years ($P = .02$) (Table 2). Although more males than females were co-infected with HBV, the
95 differences were not significant (males 13.8%, females 11.6%; $P = .59$).

96 Table 2: HIV/HBV co-infection based on age groups.

Age group	Total (%)	HIV alone	HIV/HBV
<1 year	94 (20.8)	85	9
1-5 years	227 (50.8)	200	27

6-10 years	111 (24.6)	96	15
11-15 years	20 (4.4)	13	7

97 $\chi^2 = 9.17$ P value = .02

98 The median viral load was 4.6 log copies/mL (range, 3.8-6.8 log copies/mL) for mono-infected
99 compared to 4.7 log copies/mL (range, 3.6-6.1 log copies/mL) for HIV/HBV ($P = .48$).

100 The median CD4⁺T cell count was 366 cells/ μ L (range, 4-2322 cells/ μ L) for mono-infected
101 compared to 332 cells/ μ L (range, 22-1891 cells/ μ L) for HIV/HBV ($P = .64$). The median CD4⁺T
102 cell % was 19% (range, 1-68%) for mono-infected compared to 17% (range, 2-66%) for
103 HIV/HBV ($P = .29$).

104 The median ALT level was 23 IU/L (range 2-155 IU/L) for mono-infected compared to 26 IU/L
105 (range, 2-198 IU/L) for HIV/HBV ($P = .15$). Seventy-eight (17.3%) children had elevated ALT
106 (>41IU/L in JUTH) but there was no difference in the groups: This comprises of 63 (16.8%) of
107 children with HIV alone and 15 (19.2%) of co-infected children ($P = .73$).

108 HBV co-infection was not associated with a reduced CD4⁺T cell count or CD4⁺T cell %, or a
109 higher viral load. Co-infection with HBV was however associated with significantly higher
110 median ALT level among children aged 11-15 years (Tables 3).

111 Table 3: Co-infection status and median values of different parameters based on age group.

Characteristics	HIV alone	HIV/HBV	P value
	n= 394	n= 58	
Median (range) viral load [^]			

<1year	5.6 (4.1-6.8)	5.8 (4.5-6.1)	.48
1-5years	4.5 (3.8-5.4)	4.4 (3.5-5.1)	.86
6-10years	4.7 (3.9-6.2)	4.9 (3.8-6.0)	.31
11-15years	5.1 (4.0-6.5)	5.2 (4.2-6.6)	.57
Median (range) CD4 ⁺ T *			
6-10years	372 (36-1322)	354 (22-1291)	.74
11-15years	237 (4-896)	225 (22-754)	.91
Median (range) CD4 ⁺ %			
<1years	12 (1-68)	15 (2-66)	.69
1-5years	18 (3-42)	21 (2-54)	.54
Median (range) ALT [#]			
<1years	26 (2-155)	24 (2-163)	.15
1-5years	21 (8-96)	22 (12-107)	.77
6-10years	23 (2-133)	25 (2-127)	.36
11-15years	28 (4-112)	43 (14-198)	.008

^ = log copies/mL

* = cells/μL

= IU/L

4. DISCUSSION

The prevalence rate of HIV/HBV co-infection in this cohort was 12.8%. The prevalence rate is higher than the rate of 7.7% in children in Benin [5] and 5.8% in Owerri [16] in Nigeria, 1.2% in Tanzania [7], and 4.0% in Kenya. [17] However the rate is lower than HBV prevalence rate of 19.6% reported by Angyo [18] in Jos in 1995 before the inclusion of HBV immunization in the national programme on immunization in 2004, the HIV status of the children were however not

determined. There was no prevalence study in the general population in children in Jos since implementation of HBV immunization to compare with the present study.

Children in sub-Saharan African countries share similar socio-demographical characteristics that increase the risk of HBV infection. These include transfusion of unscreened blood, injections with contaminated needles and syringes, traditional uvulectomy and scarifications, circumcision and ear piercing with contaminated instruments, frequent skin ulcerations, and sharing of toothbrushes, bath towels and beds. The difference in the prevalence rate of HIV/HBV co-infection in this study and those of other studies may reflect the differences in the geographical distribution and the methodologies as well as the different sensitivities of tests employed.

A significant number of our patients that were co-infected with HBV were found to be adolescents between the ages of 11–15 years. A similar trend was noticed by Zhou [19] in China where children older than 11 years were significantly more infected with HBV. Toussi [20] also found that children who were HIV/HBV co-infected had a higher median age of 17 years compared to HIV mono-infected children with a median age of 11.4 years in USA. Hepatitis B vaccine was first introduced as part of the National Program on Immunization in Nigeria in 2004, and this may partly explain the reason for a higher HBV co-infection among children within 11–15 years group.

No significant difference was observed in the rate of co-infection with HBV between males and females. This is similar to what was reported in Makurdi, Nigeria. [21]

We did not observe any significant difference in the median viral load, CD4⁺T cell count and CD4⁺T cell % of mono and co-infected patients. This is similar with what was reported elsewhere in developing countries. [21-23] Toussi [20] however reported that HIV/HBV co-

infected children had a lower CD4% and a higher HIV RNA levels than their mono-infected counterparts in USA.

In this study, 17.3% of the patients had elevated ALT levels. This is comprised of 16.8% of mono-infected patients and 18.3% of co-infected patients. Looking at the whole cohort, HBV co-infected patients had a slightly higher median ALT level compared to mono-infected patients, but the differences were not significant. This is similar to earlier reports in developing countries and China. [19, 21, 23] In Tanzania [7] elevated ALT value was shown to be associated with HIV/HBV co-infections in the univariate analysis but not in multivariate analysis. However, a report from USA [20] showed that HBV co-infected children were more likely to have mildly elevated transaminase levels (50%), compared to mono-infected group (19%). Studies have shown that childhood-acquired chronic HBV infection has a long inactive carrier phase; and that acute exacerbation of chronic HBV infection, with reactivation of HBV replication and re-elevation of ALT levels is relatively rare in children, in comparison to adults. [24-27] We however observed that HBV co-infected patients aged 11-15 years had a significantly higher ALT levels compared to mono-infected patients of same age. This may indicate that some of them either had acute HBV infection or reactivation of chronic hepatitis with active viral replication. The HBV co-infected patients with elevated ALT levels were referred to the gastroenterology unit for further evaluation.

The World Health Organization [28] recently recommended including tenofovir (TDF) in initial ARV regimens for children ≥ 3 years with HBV co-infection as it offers the potential advantage of reducing the selection of HIV resistance to lamivudine (3TC) that may compromise future options for HBV treatment. Presently in Nigeria, TDF is only recommended for adolescents ≥ 12 years of age. [29] With the availability of TDF in the powder form, countries with high prevalence rate of HIV/HBV co-infection like Nigeria should incorporate this recommendation in their

guideline on paediatric ART. Harmonizing treatment recommendations with adult regimens could improve children's access to ART. [28] Other benefits of TDF include the ability to combine it with 3TC and efavirenz (EFV) to create a potent once-daily regimen for children as it will improve adherence. [30] In addition, the fact that HIV resistance to TDF can enhance the antiviral effect of AZT may make TDF a good choice for first-line therapy in terms of sequencing NRTIs from first- to second-line regimens [31-32].

Going forward it will be desirable to do a longitudinal study to determine the impact HBV co-infection has on HIV treatment response and hepatotoxicity to anti-retroviral drugs in children.

5. CONCLUSION

A high rate of HBV co-infection was observed in HIV-infected children in this study; however more severe HIV disease was not observed. Older children co-infected with HBV had significantly higher ALT levels compared to their mono-infected counterparts. Early detection is therefore necessary in order to develop an appropriate treatment plan for children co-infected with HIV and HBV especially as they grow into adolescence.

ACKNOWLEDGEMENT

This work was funded in part by the US Department of Health and Human Services, Health Resources and Services Administration (U51HA02522) and CDC through APIN (PS 001058). The contents are solely the responsibility of the authors and do not represent the official views of the funding institutions.

REFERENCES

1. WHO Report: 1996: Fighting disease, fostering development. Geneva: World Health Organization. 1996.

2. Lee WM. Hepatitis B virus infection. *N Engl J Med*. 1997; 337: 1733-45.
3. Global HIV/AIDS Response, "Epidemic update and health sector progress towards Universal Access," UNAIDS Progress Report, 2011.
4. World Health Organization, *Introduction of Hepatitis B into Childhood Immunization Services: Management Guidelines, Including Information for Health Workers and Parents*, World Health Organization, Geneva, Switzerland, 2001.
5. Sadoh AE, Sadoh WE, Iduoriyekemwen N J. HIV co-infection with hepatitis B and C viruses among Nigerian children in an antiretroviral treatment programme. *SAJCH*. 2011; 5(1):7-10.
6. Ogboghodo BC, Aigbirior MR, Bazuaye GN, Ebomoyi MI, Iyave VI. Human immunodeficiency virus-1 co-infection in children in Benin City. *African Journal of Biomedical Research*. 2009; 12: 1-6.
7. Telatela SP, Matee MI, Munubhi EK. Seroprevalence of hepatitis B and C viral coinfections among children infected with human immunodeficiency virus attending the paediatric HIV care and treatment center at Muhimbili National Hospital in Dar-es-Salaam, Tanzania. *BMC Public Health*. 2007; 7: 338-343.
8. Rouet F, Chaix M, Inwoley A, et al. Frequent occurrence of chronic hepatitis B virus infection among West African HIV type 1 infected children. *Clin Infect Dis*. 2008; 46: 361-366.
9. Feld JJ, Ocama P, Ronald A. The liver in HIV in Africa. *Antivir Ther*. 2005; 10: 953-965.
10. Thio CL. Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. *Semin Liver Dis*. 2003; 23: 125-36.

11. Gilson, RJ, Hawkins, AE, Beecham, MR, Ross E, Waite J, Briggs M, McNally T, Kelly GE, Tedder RS, Weller IV. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. *AIDS*. 1997; 11: 597-606.
12. Kellerman, SE, Hanson DL, Mcnaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. *J Infect Dis*. 2003; 188: 571-577.
13. Ladep NG, Agaba PA, Agbaji O, Muazu A, Ugoagwu P, Imade G et al. Rates and impact of hepatitis on HIV infection in a large African cohort. *World J Gastroenterol*. 2013; 19(10): 1602–1610.
14. Idoko J, Meloni S, Muazu M, Nimzing L, Badung B, Hawkins C, Sankalé JL, Ekong E, Murphy R, Kanki P, et al. Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. *Clin Infect Dis*. 2009; 49: 1268–1273.
15. Adewole OO, Anteyi E, Ajuwon Z, Wada I, Elegba F, Ahmed P. Hepatitis B and C virus co-infection in Nigerian patients with HIV infection. *J Infect Dev Ctries* 2009; 3(5):369-375.
16. Nwolisa E, Mbanefo F, Ezeogu J, Amadi P. Prevalence of hepatitis B co-infection amongst HIV-infected children attending a care and treatment centre in Owerri, South-eastern Nigeria. *Pan African Med J*. 2013; 14: 89.
17. R. Chakraborty, G. Rees, D. Bourboulia et al., “Viral coinfections among African children infected with human immunodeficiency virus type 1,” *Clinical Infectious Diseases*. 2003; 36: 922–924.

18. Angyo AI, Okuonghae HO, Szlachetka R, Yakubu AM. Hepatitis B surface Antigenaemia in Jos. *Nig J Paed.* 1995; 22: 42-6.
19. Zhou S, Zhao Y, He Y. Hepatitis B and hepatitis C seroprevalence in children receiving antiretroviral therapy for human immunodeficiency virus-1 infection in China. *Journal of Acquired Immune Deficiency Syndromes.* 2010; 54: 191–196.
20. Toussi SS, Abadi J, Rosenberg M, Levanon D: Prevalence of Hepatitis B and C Virus Infections in Children Infected with HIV. *Clin Inf Dis.* 2007; 45:795-798.
21. Rouet F, Chaix M, Inwoley A. Frequent occurrence of chronic Hepatitis B virus infection among West African HIV type-1 infected children. *Clin Infect Dis.* 2008; 46:361-366.
22. Anigilaje EA, Olutola A. Prevalence and clinical and immunovirological profile of human immunodeficiency virus-hepatitis B co-infection among children in an antiretroviral therapy programme in Benue State, Nigeria. *ISRN Pediatrics.* 2013; 10: 81-88.
23. Sadoh AE, Sadoh WE, Iduoriyekemwen NJ. Some laboratory features of HIV infected Nigerian children co-infected with hepatitis B and C. *Annales of Biomedical Sciences.* 2012; 11: 29-39.
24. Bortolotti F, Guido M, Bartolacci S et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study.
25. Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. *Liver Int.* 2009; 29: 100-7.
26. Bortolotti F, Cadrobbi P, Crivellaro C et al. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. *Gastroenterology.* 1990; 99: 805-10.

- 258 27. Pan CQ, Zhang JX. Natural History and Clinical Consequences of Hepatitis B Virus
259 Infection. *Int J Med Sci* 2005; 2: 36-40.
- 260 28. Consolidated guideline on the use of anti-retroviral drugs for treating and preventing HIV
261 infection. Recommendations for a public health approach. Geneva, World Health
262 Organization. 2013.
- 263 29. Federal Ministry of Health: Nigeria: National Guidelines for Paediatric HIV and AIDS
264 Treatment and Care. 2010.
- 265 30. Use of tenofovir in HIV-infected children and adolescents: a public health perspective –
266 technical update on treatment optimization. Geneva, World Health Organization, 2012.
- 267 31. Martin A. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-
268 lamivudine: a randomized, 96-week trial. *Clinical Infectious Diseases*. 2009; 49:1591–
269 1601.
- 270 32. Fitzgerald F, Penazzato M, Gibb D. Development of antiretroviral resistance in children
271 with HIV in low- and middle-income countries. *Journal of Infectious Diseases*. 2013; 207:
272 S85-92.